MiniMed Is A Beautiful Business Being Traded Like It's Going Bankrupt

# MiniMed Is A Beautiful Business Being Traded Like It's Going Bankrupt

There's a stock on Nasdaq right now that is simultaneously the best-documented bull case and the most credible bear case in diabetes tech, and the market hasn't figured out which one to believe. That's MiniMed Group (MMED), the spun-out diabetes company that just posted its first quarter as an independent entity and then watched its shares get dragged out of the sauna and into the snow.

Let's start with what actually happened, because the story is stranger than either the bulls or the bears are admitting.

MiniMed reported Q1 FY2027 on September 1, and the top line was a showpiece. Net sales of $843 million, up roughly 16% organically, with U.S. growth accelerating to 13% from a limp 1.5% the quarter before. Management even raised full-year organic growth guidance to 10.5%. Nine analysts — BofA, Mizuho, BTIG, Wells Fargo, Morgan Stanley, UBS, Deutsche Bank, Evercore, Citi, Truist — all hiked targets, with Truist calling it "one of the most catalyst-rich stories in diabetes and medtech." Average target came in around $25 to $26, with a $29 ceiling from Truist. On paper, that's a stock that should be ripping toward $25.

It is sitting at $19.70.

Here's the thing that keeps me up at night about this name: the business is fine, and the tape is screaming. MiniMed made a U-shaped recovery from around $11 in May to a $24.40 high in early September. Then it rolled over like a car that hit a patch of black ice — a classic blow-off-top and distribution. It's now below its 20-day and 50-day moving averages, down hard on the month, and the sell-off looks like it might still be finding legs.

So what gives? Why would a company with 16% organic growth, a 57% gross margin, a pump line that's suddenly converting rivals' patients in droves, and a pipeline landing early get punished so mercilessly?

Two reasons, and they're both real.

First, the cash flow is ugly, and nobody's pretending it isn't. MiniLogically, MiniMed lost $90 million in free cash flow last quarter. Adjusted EBITDA margin compressed to a thin 9.9%. But here's the nuance the bears are underweighting: about $111 million of that burn was one-time separation and standup cost. Absent the carve-out, MiniMed would have been roughly cash-flow breakeven at +$21 million. The rest of the damage came from pulled-forward spending, a $12 million currency charge, and a lower-margin sensor mix. This is a company paying to become independent, and it's doing so in public.

Second, and bigger, is the Medtronic split-off. Medtronic still owns roughly 90% of MiniMed, and in mid-September it launched an exchange offer to split off at least 80.1% of the shares at a 7% discount, with an upper ratio cap of 4.5939 MMED shares per MDT share. The offer expired October 9, with the final ratio set off a VWAP of October 5 through 7. If it came in undersubscribed, Medtronic may have had to spin off its remaining shares instead. That's a live corporate event sitting on the calendar, and it introduces a whole menu of execution risk — VWAP-based pricing, proration on oversubscription, odd-lot and fractional-share headaches, expiration risk. Short interest also spiked to somewhere between 20% and 50% of float depending on which source you trust, which is a genuine camp of skeptics who are not afraid to be wrong in public.

Now, I want to make my point plainly, because I think most people are overweighting the noise and underweighting the machine.

MiniMed is the only company that commercializes every piece of an integrated diabetes system — pump, pen, continuous monitor, dosing software. That's not a marketing line; it's a distribution and switching-cost moat. Flex began shipping in late June, U.S. new-pump sales jumped over 20% year over year, Flex prescribers rose 24%, and the global CGM attachment rate hit 69%. The MiniMed Fit patch pump submitted its FDA filing ahead of schedule, Vivera completed enrollment early with patients hitting 74% time-in-range, and a next-generation extended-wear sensor got its IDE approval. This is a company running its pipeline on a fast clock.

But a fast pipeline doesn't pay for the fact that MiniMed just separated from its parent with a thin balance sheet — $207 million cash against $90 million debt, though $635 million in working capital and a 1.81 current ratio keep it from looking fragile. And only 17 of 160 transition service agreements with Medtronic have been exited. Most don't wrap until 2027. This is not a clean break; it's a messy divorce being mediated in real time.

My view? This is a long-term optionality story being fought in a near-term cash-flow and technical grinder. The business quality is real, the growth is real, and the carve-out discount on the tape is, I think, over-applied. But "real" doesn't mean "buy the breakout today." MiniMed needs to reclaim $20.40 on volume to convince me the pullback is over. Below $19.30, you're into gap risk toward that $16.80 zone that used to be resistance and now is support.

I'd rather own the story than chase the tape. Add in small size on a reclaim of $20.40 or a dip into the $19.00–19.30 support, and stay out of any FOMO. If it breaks $18.80, the thesis for a tactical buyer gets a lot less generous.

The market is arguing about whether MiniMed is a carve-out casualty or a carve-out opportunity. Both can be right. The only thing I won't do is pretend the chart and the cash flow don't matter just because the pipeline is spectacular. In medtech, the best idea in the world still dies in the value trap if you pay too much and the separation drags.

Own it patient. Chase it at your own risk.